Collection 4 (Sep 2023 - Aug 2024) Articles

Articles
Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality
Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, et al.
Journal:
N Engl J Med

First published: October 5, 2023 DOI: 10.1056/NEJMoa2206916
View
- Share
Articles
A comparison of laboratory-based and office-based Framingham risk scores to predict 10-year risk of cardiovascular diseases: a population-based study
Dehghan A, Ahmadnia Motlagh S, Khezri R, et al.
Journal:
J Transl Med

First published: October 3, 2023 DOI: 10.1186/s12967-023-04568-8
View
- Share
Articles
LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals
Andersson NW, Corn G, Dohlmann TL, et al.
Journal:
J Am Coll Cardiol

First published: October 3, 2023 DOI: 10.1016/j.jacc.2023.07.027
View
- Share
Articles
The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived
Ridker PM
Journal:
Circulation

First published: October 2, 2023 DOI: 10.1161/CIRCULATIONAHA.123.066510
View
- Share
Articles
Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
Wadström BN, Pedersen KM, Wulff AB, et al.
Journal:
Diabetologia

First published: September 30, 2023 DOI: 10.1007/s00125-023-06016-0
View
- Share
Articles
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström BN, Wulff AB, Pedersen KM, et al.
Journal:
Curr Atheroscler Rep

First published: September 28, 2023 DOI: 10.1007/s11883-023-01153-8
View
- Share
Articles
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
Su Q, Liu Y, Zhang G, et al.
Journal:
Adv Ther

First published: September 28, 2023 DOI: 10.1007/s12325-023-02666-z
View
- Share
Articles
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review
Figtree GA, Vernon ST, Harmer JA, et al.
Journal:
J Am Coll Cardiol

First published: September 26, 2023 DOI: 10.1016/j.jacc.2023.06.045
View
- Share
Articles
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics
Nicholls SJ, Bhatt DL, Buse JB, et al.
Journal:
Am Heart J

First published: September 25, 2023 DOI: 10.1016/j.ahj.2023.09.007
View
- Share
Articles
First clinical experiences with inclisiran in a real-world setting
Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE
Journal:
J Clin Lipidol

First published: September 18, 2023 DOI: 10.1016/j.jacl.2023.09.005
View
- Share
Articles
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial
Goodman SG, Steg PG, Poulouin Y, et al.
Journal:
J Am Heart Assoc

First published: September 13, 2023 DOI: 10.1161/JAHA.122.029216
View
- Share

1 … 10 11 12

Collection 4 (Sep 2023 - Aug 2024) Articles

Articles

Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality

Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, et al.

Articles

A comparison of laboratory-based and office-based Framingham risk scores to predict 10-year risk of cardiovascular diseases: a population-based study

Dehghan A, Ahmadnia Motlagh S, Khezri R, et al.

Articles

LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals

Andersson NW, Corn G, Dohlmann TL, et al.

Articles

The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

Ridker PM

Articles

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study

Wadström BN, Pedersen KM, Wulff AB, et al.

Articles

Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?

Wadström BN, Wulff AB, Pedersen KM, et al.

Articles

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial

Su Q, Liu Y, Zhang G, et al.

Articles

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Figtree GA, Vernon ST, Harmer JA, et al.

Articles

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Nicholls SJ, Bhatt DL, Buse JB, et al.

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Articles

Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality

Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, et al.

Share

Articles

A comparison of laboratory-based and office-based Framingham risk scores to predict 10-year risk of cardiovascular diseases: a population-based study

Dehghan A, Ahmadnia Motlagh S, Khezri R, et al.

Share

Articles

LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals

Andersson NW, Corn G, Dohlmann TL, et al.

Share

Articles

The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

Ridker PM

Share

Articles

Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study

Wadström BN, Pedersen KM, Wulff AB, et al.

Share

Articles

Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?

Wadström BN, Wulff AB, Pedersen KM, et al.

Share

Articles

Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial

Su Q, Liu Y, Zhang G, et al.

Share

Articles

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Figtree GA, Vernon ST, Harmer JA, et al.

Share

Articles

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Nicholls SJ, Bhatt DL, Buse JB, et al.

Share

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Share

Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

Share